top of page
Buscar

Eli Lilly signs oncology research partnership with Stipple Bio carrying up to $5.9 billion in potential milestones

Foto del escritor: nuaxia
nuaxia
hace 5 minutos
1 min de lectura

Eli Lilly has entered a multi-target oncology research collaboration with Stipple Bio carrying up to $5.9 billion in potential milestone payments, centred on the discovery of tumour-specific therapeutic targets.


Stipple Bio announced on 16 November 2026 that it had signed a research collaboration and licensing agreement granting Eli Lilly exclusive worldwide rights to develop and commercialise products arising from Stipple's Pointillist tumour-specific epitope discovery platform across multiple oncology targets and therapeutic modalities.


Stipple will receive an undisclosed upfront payment and equity investment and may earn up to $5.9 billion in research, development and commercial milestone payments alongside tiered royalties; the agreement is a discovery and licensing partnership rather than an acquisition, and the headline milestone value is contingent on future achievements.

Field

Content

Partner One

Eli Lilly

Partner Two

Stipple Bio

Announcement Date

16 November 2026

Agreement Type

Multi-target research collaboration and licensing

Therapeutic Area

Oncology

Technology Platform

Pointillist

Platform Focus

Discovery of tumour-specific epitopes

Research Scope

Multiple oncology targets and therapeutic modalities

Licensed Rights

Exclusive worldwide development and commercialisation rights to resulting products

Upfront Payment

Undisclosed

Equity Investment

Included; amount undisclosed

Potential Milestone Payments

Up to $5.9 billion

Milestone Categories

Research development and commercial

Additional Consideration

Tiered royalties

Financial Conditions

Most headline value is contingent on future milestones

Strategic Significance

Supports discovery of precision oncology medicines targeting tumour-specific biology

Primary Source

https://stipple.bio/stipple-bio-announces-multi-target-multi-modality-oncology-research-collaboration-with-lilly/


Discover how nuaxia can support your next medical education initiative:

 
 
 

Comentarios

Obtuvo 0 de 5 estrellas.
Aún no hay calificaciones

Agrega una calificación
bottom of page